Introduction: Daratumumab (DARA) is a human IgG1κ monoclonal antibody that binds with high affinity to a unique epitope on...
Better Medicines Through Signaling Dynamics
13
Years in business
2
Therapeutic Areas
40
Publications
Immuneering’s novel drug candidates spare healthy normal cells by modulating signaling dynamics to focus therapeutic impact against tumor cells.
Platform
Immuneering’s innovative R&D platform has a long history of reproducibly identifying drug targets, pinpointing biomarkers, stratifying patients and elucidating drug mechanisms of action. Currently, our platform is employed to drive Immuneering’s internal pipeline and those of our high value R&D relationships with select partners.
Publications
Our commitment to rigor and reproducible data analysis is validated by a long track record of peer-reviewed publications. In collaboration with our partners in pharma and the scientific community, our research has been featured in a number of high-impact journals.
Publications
A primer on applying AI synergistically with domain expertise to oncology
Abstract Background The concurrent growth of large-scale oncology data alongside the computational methods with which to analyze and model...
Oncopanel genomic testing, which identifies important somatic variants, is increasingly common in medical practice and especially in clinical trials....
Background Targeted sequencing using oncopanels requires comprehensive assessments of accuracy and detection sensitivity to ensure analytical validity. By employing...
Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
Circulating tumor DNA (ctDNA) sequencing is being rapidly adopted in precision oncology, but the accuracy, sensitivity and reproducibility of...
Breakthroughs in artificial intelligence (AI) hold enormous potential as it can automate complex tasks and go even beyond human...
Oncolytic viruses (OVs) are a new class of cancer therapeutics. This review was undertaken to provide insight into the...
pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model
Huntington disease (HD), a devastating hereditary neurodegenerative disorder, is caused by an expansion of a CAG trinucleotide repeat that...
Endocrine-disrupting chemicals (EDCs) can interact with nuclear receptors, including estrogen receptor α (ERα) and androgen receptor (AR), to affect...
The recent global pandemic has placed a high priority on identifying drugs to prevent or lessen clinical infection of...
